Mary Beth Nierengarten is a writer, editor and journalist with over 25 years of medical communications experience. She is a regular contributor to a number of online and print publications and writes in most clinical areas, as well as on health policy and economic issues. She lives in Minneapolis and can be reached at mbeth@visi.com.
A note from ARP President Hazel L. Breland, PhD, OTR/L, FAOTA: Some time has passed since the ACR first published its NP/PA Rheumatology Curriculum Outline. Originally developed to serve as a guide for rheumatologists to onboard a nurse practitioner (NP) or physician assistant (PA) into the rheumatology practice setting, the ACR has realized this valuable resource… [Read More]
Genes may predispose people to have certain microbial signatures in their gut that, in turn, make them susceptible to developing reactive arthritis. This is the main finding of a recent study in which researchers investigated whether perturbations in the intestinal microbiome play a role in susceptibility to reactive arthritis in the face of triggers, such… [Read More]
Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA. Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating… [Read More]
Higher anxiety levels in postmenopausal women may put them at increased risk of fracture and should be considered when assessing a woman’s risk of osteoporosis as well. This is the conclusion of a study recently published in the journal Menopause that looked at the role of anxiety in bone health.1 Specifically, the study examined the… [Read More]
It has long been known that hyperlipidemia adversely affects bone, but the exact pathologic mechanism(s) underlying hyperlipidemia-induced bone loss has not been fully understood. Until now. Pathogenesis of Osteoporosis New research by Ambrogini and colleagues shows that oxidation-specific epitopes derived from lipid peroxidation contribute to the pathogenesis of osteoporosis.1 Importantly, the research shows that innate… [Read More]
For patients with rheumatoid arthritis (RA) who respond to subcutaneous tocilizumab, discontinuing methotrexate may be an option and offer an alternative to patients who cannot tolerate or prefer not to take methotrexate. “This is one of the first studies showing that methotrexate may be discontinued in a cohort of patients with a biologic agent without… [Read More]
A confluence of advances in knowledge and technology is closing in on the day when therapies for patients with rheumatoid arthritis (RA) may be specifically targeted to the precise variant and stage of disease. “Precision medicine is in the future, and not the distant future but more in the immediate future,” says Harris R. Perlman,… [Read More]
Studies highlighting the large numbers of people affected by knee osteoarthritis (OA) point to what clinicians who treat knee OA have been seeing for the past few decades: a substantial increase in the prevalence of knee OA in the U.S. and globally. Roughly 250 million people are affected by knee OA worldwide, and about 14… [Read More]
The data tell the story. Despite improvements in overall outcomes for common rheumatologic conditions, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), white patients fare better than minority patients, and sometimes substantially better. Even with new biologic therapies that have significantly altered the course of disease for patients with RA, outcomes for minorities… [Read More]
A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease. Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the… [Read More]